Ignite Creation Date:
2025-12-24 @ 11:10 PM
Ignite Modification Date:
2025-12-25 @ 8:43 PM
Study NCT ID:
NCT00277069
Status:
COMPLETED
Last Update Posted:
2010-01-07
First Post:
2006-01-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer
Sponsor:
University of New Mexico
Organization:
Study Overview
Official Title:
INST: Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1\. Determine the response rate with this regimen in an anthracycline and taxane resistant cohort of patients.
Detailed Description:
1. Determine the response rate with this regimen in an anthracycline and taxane resistant cohort of patients.
2. Determine a maximum tolerated dose of capecitabine in combination with vinorelbine and carboplatin for this patient population.
3. Determine the time to relapse after the administration of this regimen.
2. Determine a maximum tolerated dose of capecitabine in combination with vinorelbine and carboplatin for this patient population.
3. Determine the time to relapse after the administration of this regimen.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: